Meiwei Bio: The clinical trial application for 9MW3811 Injection for pathologic scars phase II has been approved.

Mawei Biotech announced that it has recently received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for the Phase II clinical trial application of the 9MW3811 injection for pathological scar indications. The drug is a humanized monoclonal antibody targeting human IL-11 developed independently by Mawei Biotech, which has been approved for late-stage malignant tumors and idiopathic pulmonary fibrosis clinical studies worldwide. The company plans to start its Phase II clinical trials for pathological scars by the end of 2025. In addition, the company has reached an exclusive license agreement with CALICO, receiving an initial payment of $25 million, with potential milestone payments of up to $571 million and licensing fees.